|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
R, Torre L and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Powles T, Albiges L, Staehler M, Bensalah
K, Dabestani S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Lam TB, et
al: Updated European association of urology guidelines:
Recommendations for the treatment of first-line metastatic clear
cell renal cancer. Eur Urol. 73:311–315. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cho DH, Jo YK, Roh SA, Na YS, Kim TW, Jang
SJ, Kim YS and Kim JC: Upregulation of SPRR3 promotes colorectal
tumorigenesis. Mol Med. 16:271–277. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kim JC, Yu JH, Cho YK, Jung CS, Ahn SH,
Gong G, Kim YS and Cho DH: Expression of SPRR3 is associated with
tumor cell proliferation in less advanced stages of breast cancer.
Breast Cancer Res Treat. 133:909–916. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu Q, Zhang C, Ma G and Zhang Q:
Expression of SPRR3 is associated with tumor cell proliferation and
invasion in glioblastoma multiforme. Oncol Lett. 7:427–432.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li Q, Wang Y, Hu R and Yang G:
Dysregulation of SPRR3/miR-876-3p axis contributes to tumorigenesis
in non-small-cell lung cancer. Onco Targets Ther. 13:2411–2419.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang Y, Feng YB, Shen XM, Chen BS, Du XL,
Luo ML, Cai Y, Han YL, Xu X, Zhan QM, et al: Exogenous expression
of Esophagin/SPRR3 attenuates the tumorigenicity of esophageal
squamous cell carcinoma cells via promoting apoptosis. Int J
Cancer. 122:260–266. 2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Segedy AK, Pyle AL, Li B, Zhang Y, Babaev
VR, Jat P, Fazio S, Atkinson JB, Linton MF and Young PP: .
Identification of small proline-rich repeat protein 3 as a novel
atheroprotective factor that promotes adaptive Akt signaling in
vascular smooth muscle cells. Arterioscler Thromb Vasc Biol.
34:2527–2536. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Saraswati S, Lietman C, Li B, Mathew S,
Zent R and Young P: Small proline-rich repeat 3 is a novel
coordinator of PDGFRβ and integrin β1 crosstalk to augment
proliferation and matrix synthesis by cardiac fibroblasts. FASEB J.
34:7885–7904. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Harrandah A, Mora R and Chan E: Emerging
microRNAs in cancer diagnosis, progression, and immune
surveillance. Cancer Lett. 438:126–132. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tong Z, Meng X, Wang J and Wang L:
MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and
invasion of renal cell carcinoma. Exp Ther Med. 14:5200–5206.
2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang X, Zhang Y and Fan H: Downregulation
of SBF2-AS1 functions as a tumor suppressor in clear cell renal
cell carcinoma by inhibiting miR-338-3p-targeted ETS1. Cancer Gene
Ther. 28:813–827. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhu Q, Zhan D, Zhu P, Chong Y and Yang Y:
CircAKT1 acts as a sponge of miR-338-3p to facilitate clear cell
renal cell carcinoma progression by up-regulating CAV1. Biochem
Biophys Res Commun. 532:584–590. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Peng X, Yang J, Qiang Y, Sun R, Cao Y,
Zheng LS, Peng LX, Lang YH, Mei Y, Li CZ, et al: PTPN3 inhibits the
growth and metastasis of clear cell renal cell carcinoma via
inhibition of PI3K/AKT signaling. Mol Cancer Res. 18:903–912.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li G, Chong T, Yang J, Li H and Chen H:
Kinesin motor protein KIFC1 is a target protein of miR-338-3p and
is associated with poor prognosis and progression of renal cell
carcinoma. Oncol Res. 27:125–137. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Agarwal V, Bell G, Nam J and Bartel D:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4(e05005)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang L, Sui M and Wang X: miR-338-3p
suppresses the malignancy of T-cell lymphoblastic lymphoma by
downregulating HOXA3. Mol Med Rep. 20:2127–2134. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chen BS, Wang MR, Cai Y, Xu X, Xu ZX, Han
YL and Wu M: Decreased expression of SPRR3 in Chinese human
oesophageal cancer. Carcinogenesis. 21:2147–2150. 2000.PubMed/NCBI View Article : Google Scholar
|
|
23
|
de A Simão T, Souza-Santos PT, de Oliveira
DS, Bernardo V, Lima SC, Rapozo DC, Kruel CD, Faria PA, Ribeiro
Pinto LF and Albano RM: Quantitative evaluation of SPRR3 expression
in esophageal squamous cell carcinoma by qPCR and its potential use
as a biomarker. Exp Mol Pathol. 91:584–589. 2011.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hohl D, de Viragh P, Amiguet-Barras F,
Gibbs S, Backendorf C and Huber M: The small proline-rich proteins
constitute a multigene family of differentially regulated cornified
cell envelope precursor proteins. J Invest Dermatol. 104:902–909.
1995.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ellis R, Tang D, Nasr B, Greenwood A,
McConnell A, Anagnostou ME, Elias M, Verykiou S, Bajwa D, Ewen T,
et al: Epidermal autophagy and beclin 1 regulator 1 and loricrin: A
paradigm shift in the prognostication and stratification of the
American joint committee on cancer stage I melanomas. Br J
Dermatol. 182:156–165. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Huang Y, Wu Y, Zeng L, Shan W and Huang L:
The tumor suppressor role of microRNA-338-3p in renal cell
carcinoma. Oncol Lett. 16:2195–2200. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
He J, Wang J, Li S, Li T, Chen K and Zhang
S: Hypoxia-inhibited miR-338-3p suppresses breast cancer
progression by directly targeting ZEB2. Cancer Sci. 111:3550–3563.
2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Xu Z, Sun Y, Wang D, Sun H and Liu X:
SNHG16 promotes tumorigenesis and cisplatin resistance by
regulating miR-338-3p/PLK4 pathway in neuroblastoma cells. Cancer
Cell Int. 20(236)2020.PubMed/NCBI View Article : Google Scholar
|
